trial · primary record
Surovatamig
Large B-cell Lymphoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1200 |
| Primary completion | 2032-09-01 |
| Primary endpoint | Progression free survival (PFS) as assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT07911553 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:04.274Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07911553
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.